Biohaven (BHVN) Competitors $14.77 +0.81 (+5.80%) Closing price 03:59 PM EasternExtended Trading$14.94 +0.17 (+1.16%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BHVN vs. TGTX, LNTH, NUVL, TLX, AXSM, ADMA, AKRO, PCVX, RYTM, and KRYSShould you be buying Biohaven stock or one of its competitors? The main competitors of Biohaven include TG Therapeutics (TGTX), Lantheus (LNTH), Nuvalent (NUVL), Telix Pharmaceuticals (TLX), Axsome Therapeutics (AXSM), ADMA Biologics (ADMA), Akero Therapeutics (AKRO), Vaxcyte (PCVX), Rhythm Pharmaceuticals (RYTM), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry. Biohaven vs. Its Competitors TG Therapeutics Lantheus Nuvalent Telix Pharmaceuticals Axsome Therapeutics ADMA Biologics Akero Therapeutics Vaxcyte Rhythm Pharmaceuticals Krystal Biotech TG Therapeutics (NASDAQ:TGTX) and Biohaven (NYSE:BHVN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk, analyst recommendations and media sentiment. Which has more risk and volatility, TGTX or BHVN? TG Therapeutics has a beta of 1.91, suggesting that its stock price is 91% more volatile than the S&P 500. Comparatively, Biohaven has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500. Does the media favor TGTX or BHVN? In the previous week, TG Therapeutics had 10 more articles in the media than Biohaven. MarketBeat recorded 11 mentions for TG Therapeutics and 1 mentions for Biohaven. TG Therapeutics' average media sentiment score of 0.83 beat Biohaven's score of 0.00 indicating that TG Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biohaven 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is TGTX or BHVN more profitable? TG Therapeutics has a net margin of 10.13% compared to Biohaven's net margin of 0.00%. TG Therapeutics' return on equity of 18.88% beat Biohaven's return on equity.Company Net Margins Return on Equity Return on Assets TG Therapeutics10.13% 18.88% 7.05% Biohaven N/A -257.07%-164.01% Do insiders & institutionals believe in TGTX or BHVN? 58.6% of TG Therapeutics shares are held by institutional investors. Comparatively, 88.8% of Biohaven shares are held by institutional investors. 10.6% of TG Therapeutics shares are held by company insiders. Comparatively, 14.6% of Biohaven shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts recommend TGTX or BHVN? TG Therapeutics currently has a consensus price target of $40.80, indicating a potential upside of 12.63%. Biohaven has a consensus price target of $58.46, indicating a potential upside of 295.95%. Given Biohaven's stronger consensus rating and higher probable upside, analysts plainly believe Biohaven is more favorable than TG Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TG Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Biohaven 0 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 2 Strong Buy rating(s) 3.07 Which has stronger valuation & earnings, TGTX or BHVN? TG Therapeutics has higher revenue and earnings than Biohaven. Biohaven is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTG Therapeutics$329M17.48$23.38M$0.24150.94BiohavenN/AN/A-$846.42M-$9.36-1.58 SummaryTG Therapeutics beats Biohaven on 10 of the 16 factors compared between the two stocks. Get Biohaven News Delivered to You Automatically Sign up to receive the latest news and ratings for BHVN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BHVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BHVN vs. The Competition Export to ExcelMetricBiohavenMED IndustryMedical SectorNYSE ExchangeMarket Cap$1.51B$2.90B$5.49B$20.51BDividend YieldN/A2.69%5.38%3.76%P/E Ratio-1.5821.2626.2027.81Price / SalesN/A279.34415.5037.44Price / CashN/A41.8936.4921.79Price / Book3.527.508.054.55Net Income-$846.42M-$55.05M$3.15B$984.47M7 Day Performance2.96%2.49%1.92%3.57%1 Month Performance-5.45%7.40%4.90%6.03%1 Year Performance-56.79%5.42%35.95%14.48% Biohaven Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BHVNBiohaven2.7774 of 5 stars$14.77+5.8%$58.46+295.8%-60.5%$1.51BN/A-1.58239TGTXTG Therapeutics3.7452 of 5 stars$35.99-2.0%$40.80+13.4%+95.0%$5.71B$386.39M149.96290LNTHLantheus4.4423 of 5 stars$81.86+0.5%$130.50+59.4%-0.7%$5.66B$1.53B23.26700Positive NewsNUVLNuvalent3.7087 of 5 stars$76.30-4.2%$119.60+56.7%+3.3%$5.48BN/A-17.3840Analyst UpgradeInsider TradeTLXTelix PharmaceuticalsN/A$16.07+0.4%$22.00+36.9%N/A$5.44B$516.72M0.00N/AGap DownAXSMAxsome Therapeutics4.6726 of 5 stars$104.39+1.0%$172.33+65.1%+27.1%$5.14B$432.16M-18.09380Analyst RevisionADMAADMA Biologics4.0895 of 5 stars$18.21+0.3%$27.67+51.9%+54.8%$4.35B$426.45M21.42530AKROAkero Therapeutics3.6155 of 5 stars$53.36-5.0%$82.50+54.6%+122.0%$4.25BN/A-27.3630PCVXVaxcyte1.7882 of 5 stars$32.51-0.2%$136.50+319.9%-57.2%$4.19BN/A-8.15160News CoveragePositive NewsRYTMRhythm Pharmaceuticals3.8956 of 5 stars$63.19+0.7%$77.31+22.3%+53.4%$4.02B$136.86M-22.49140KRYSKrystal Biotech4.6181 of 5 stars$137.46-1.0%$211.13+53.6%-23.7%$3.97B$333.45M33.04210Analyst Revision Related Companies and Tools Related Companies TG Therapeutics Alternatives Lantheus Alternatives Nuvalent Alternatives Telix Pharmaceuticals Alternatives Axsome Therapeutics Alternatives ADMA Biologics Alternatives Akero Therapeutics Alternatives Vaxcyte Alternatives Rhythm Pharmaceuticals Alternatives Krystal Biotech Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:BHVN) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biohaven Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biohaven With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BHVN Stock Alerts